# US 2024/0197746 A1 · Combination therapy with a mek inhibitor and a src inhibitor for the treatment of colorectal cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197746 A1
- Document ID: US20240197746A1
- Status: Published application
- Kind: A1
- Application number: 18/589,576
- Filed: 2024-02-28
- Published: 2024-06-20
- Earliest claimed: 2021-08-30
- Assignees: Yeda Research and Development Co. Ltd.; The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center
- Applicants: Yeda Research and Development Co. Ltd.; The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center
- Inventors: Ravid STRAUSSMAN; Nancy GAVERT; Yaara ZWANG
- Web page: https://patentgrep.com/patent/US20240197746A1

## CPC

- A61K 31/52: Purines, e.g. adenine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 35/00: Antineoplastic agents
- C12N 5/0679: {Cells of the gastro-intestinal tract}
- C12N 5/0693: {Tumour cells; Cancer cells}
- G01N 33/5011: {for testing antineoplastic activity}
- C12N 2500/02: Atmosphere, e.g. low oxygen conditions
- C12N 2527/00: Culture process characterised by the use of mechanical forces, e.g. strain, vibration
- G01N 2333/9121: with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A method of treating colorectal cancer (CRC) is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of a Mitogen/extracellular signal-regulated kinase (MEK) inhibitor and a SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase (SRC) inhibitor, wherein cancer cells of the subject express an amount of SRC p419 above a predetermined level and do not express a KRAS G12 mutation, thereby treating the CRC.

## Claims

### Claim 1

A method of treating colorectal cancer (CRC), the method comprising administering to a subject in need thereof a therapeutically effective amount of a Mitogen/extracellular signal-regulated kinase (MEK) inhibitor and a SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase (SRC) inhibitor, wherein cancer cells of the subject express an amount of SRC p419 above a predetermined level and do not express a KRAS G12 mutation, thereby treating the CRC.

### Claim 2

A method of selecting treatment to colorectal cancer (CRC) for a subject in need thereof, the method comprising determining a level of SRC p419 and a RAS mutation to exclude a KRAS G12 mutation in cancer cells of the subject, wherein a SRC p419 level above a predetermined level and an absence of a KRAS G12 mutation, is indicative of an efficacious treatment with of a MEK inhibitor and a SRC inhibitor.

### Claim 3 (depends on 2)

The method of claim 2, further comprising testing sensitivity to said treatment in an ex-vivo organ culture (EVOC) model.

### Claim 4 (depends on 3)

The method of claim 3, comprising any of:
(i) testing sensitivity to said MEK inhibitor and said SRC inhibitor in said EVOK model by monitoring cell killing;
(ii) testing sensitivity to said MEK inhibitor and said SRC inhibitor in cells of said EVOK model by determining a level of MEK phosphorylation (pMEK), wherein a level below a predetermined or control is indicative of an efficacious treatment; and/or
(iii) testing sensitivity to said SRC inhibitor in cells of said EVOK model by determining level ERK1/2 phosphorylation (pERK1/2), wherein a level below a predetermined or control is indicative of an efficacious treatment.

### Claim 5 (depends on 3)

The method of claim 3, wherein said EVOC model comprises culturing in a culture medium a precision-cut tissue slice of said CRC placed on a tissue culture insert, wherein said precision-cut tissue slice is maintained in a highly oxygenated atmosphere containing about 80% oxygen and wherein said culture is rotationally agitated facilitating intermittent submersion of said tissue slice in said culture medium.

### Claim 6 (depends on 5)

The method of claim 5, wherein said culture is in a tissue culture plate.

### Claim 7 (depends on 5)

The method of claim 5, wherein said culture medium comprises DMEM/F12.

### Claim 8 (depends on 5)

The method of claim 5, wherein said culturing is effected for at least 4 or 5 days.

### Claim 9 (depends on 5)

The method of claim 5, wherein said slice is in direct contact with said tissue culture insert.

### Claim 10 (depends on 5)

The method of claim 5, wherein said tissue culture insert is a titanium grid insert.

### Claim 11 (depends on 1)

The method of claim 1, wherein said cancer cells exhibit at least one of:
(i) sensitivity to said MEK inhibitor and said SRC inhibitor in an EVOK model as monitored by cell killing;
(ii) sensitivity to said MEK inhibitor and said SRC inhibitor in an EVOK model based on the level of MEK phosphorylation (pMEK), wherein a level below a predetermined or control is indicative of an efficacious treatment; and/or
(iii) sensitivity to said SRC inhibitor in an EVOK model based on the level of ERK1/2 phosphorylation (pERK1/2), wherein a level below a predetermined or control is indicative of an efficacious treatment.

### Claim 12 (depends on 1)

The method of claim 1, wherein said MEK inhibitor is selected from the group consisting of trametinib and selumetinib.

### Claim 13 (depends on 1)

The method of claim 1, wherein said SRC inhibitor is selected from the group consisting of bosutinib, dasatinib, saracotinib, ponatinib, TPX-0022 and 1-NM-PP1.

### Claim 14 (depends on 1)

The method of claim 1, further comprising treatment with Folfox or Folfiri.

### Claim 15 (depends on 1)

The method of claim 1, wherein said CRC is selected from the group consisting of locally advanced, metastatic CRC and a recurrent disease.
